2 terminated. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Terminated 2 |
| Phase 2 | 1 | Terminated 1 |
Follow B Cell Malignancies: new trials by email Literature Review of B Cell Malignancies trials Research Report on B Cell Malignancies
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CD19/79b Bi-specific CAR-T Cell Therapy bi-4SCAR CD19/79b T cells - B Cell Malignancies | Phase 1 / Phase 2 | Terminated | Shenzhen Geno-Immune Medical Institute | 60 | 2026-06-01 | 2026-08-24 |
| A Phase I Study of WT1 Peptides to Induce Anti-Leukemia Immune Responses Following Transplantation WT1 derived peptides - Acute Myelogenous Leukemia (AML), Chronic Myelogenous Leukemia (CML) | Phase 1 | Terminated | Michael Morse, MD | 8 | 2007-06-01 | 2013-12-10 |
Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Leukemia, Myeloid, Acute (1) · Myelodysplastic Syndromes (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)
Bone Marrow Diseases (1) · Chronic Disease (1) · Disease Attributes (1) · Hematologic Diseases (1) · Hemic and Lymphatic Diseases (1) · Immune System Diseases (1) · Immunoproliferative Disorders (1) · Leukemia (1) · Leukemia, Lymphoid (1) · Leukemia, Myeloid (1) · Lymphatic Diseases (1) · Lymphoproliferative Disorders (1) · Myeloproliferative Disorders (1) · Neoplasms (1) · Neoplasms by Histologic Type (1)
Michael Morse, MD (1) · Shenzhen Geno-Immune Medical Institute (1)
China (1) · United States (1)
Amy Hobeika, PhD (1) · Michael A Morse, MD (1) · Nelson Chao, MD (1)